Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 March;49(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 March;49(1):81-96

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 March;49(1):81-96

NUCLEAR CARDIOLOGY: THE PRESENT AND THE FUTURE
Guest Editors: R. Sciagr√† and J. J. Bax 

    REVIEW ARTICLES

Assessment of myocardial viability in chronic ischemic heart disease: current status

Rizzello V. 1, Poldermans D. 1, Bax J. J. 2

1 Department of Cardiology, Thoraxcenter Erasmus MC, Rotterdam, The Netherlands
2 Department of Cardiology Leiden University Medical Center, Leiden, The Netherlands

Assessment of myocardial viability is clinically important in the work-up of patients with ischemic cardiomyopathy. Numerous studies in the past 2 decades demonstrated that revascularization improves left ventricular ejection fraction (LVEF), heart failure symptoms and prognosis in patients with viable myocardium. Conversely patients without viable tissue do not benefit from revascularization. Also, a substantial amount of viable myocardium (at least 25% of the left ventricle) is needed to result in improvement of LVEF. Hence, both identification and quantification of the extent of viable myocardium are required for a careful selection of candidates for revascularization. Indeed, the presence of a substantial amount of viable myocardium decreases the risk of surgery in patients with reduced LVEF. Several diagnostic techniques are available to identify myocardial viability. Positron emission tomography (PET), myocardial perfusion imaging, and stress echocardiography are considered the traditional techniques to evaluate myocardial viability. Recently, newer techniques including cardiac magnetic resonance (CMR), myocardial contrast echocardiography (MCE) and electromechanical mapping have been introduced. In this manuscript the status of the currently available techniques to assess viability was reviewed. Also the relative merits of each technique for prediction of functional recovery and prognosis was addressed. The available retrospective data support the clinical use of viability assessment. Patients with ischemic cardiomyopathy should undergo viability testing to determine therapeutic strategy. In the presence of substantial amount of viable myocardium, patients should undergo revascularization since benefits in terms of left ventricular function, remodeling, symptoms and prognosis may be anticipated. However, prospective randomized trial are needed to confirm these data.

language: English


FULL TEXT  REPRINTS

top of page